AZ adds gene silencing tech to pipeline with Silence Therape...

AstraZeneca has announced a collaboration with UK biotech Silence Therapeutics to develop gene silencing drugs for cardiovascular, renal, metabolic and respiratory diseases.

Pharma steps up as coronavirus cases soar to 400,000-plus

FDA backs Glenmark's rival to AZ's blockbuster Farxiga

AstraZeneca’s diabetes drug Farxiga could face generic competition in the US, after the FDA gave tentative approval to a generic rival from India’s Glenmark, although it is unclear when the

AZ's immunotherapy combo fails in phase 3 lung cancer trial

AstraZeneca’s Imfinzi plus standard chemo improves overall survival in untreated extensive-stage small cell lung cancer – but a combination therapy involving another immunotherapy does not,

Coronavirus to disrupt EU pharma drug launches, analysts war...

Big European launches of drugs for cancer, HIV, and sickle cell disease could be affected by coronavirus, according to a new analysis from Jefferies.

AZ's cediranib falls short again in ovarian cancer combinati...

AstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it did not improve survival compared with chemotherapy in advanced ovarian cancer, in